Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced it will present updated interim results from their Phase 1 trial of INB-100 at the upcoming European Hematology Association (EHA) 2024 Congress in Madrid, June 13-16. INB-100 is a gamma-delta T cell therapy aimed at increasing survival and reducing cancer recurrence in leukemia patients post-haploidentical stem cell transplantation, without severe graft-versus-host disease. The presentation will be held on June 14, 2024, at 10:00 a.m. CEST by Dr. Joseph P. McGuirk. Abstracts are accessible on the EHA website, and the poster will be available on IN8bio's site following the session.
IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.
IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.
IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.